Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase EARLY_PHASE1 1Phase 3 1Phase 2 1

Status

Active not recruiting 2Suspended 1Recruiting 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 2NET 1Lymphoid 1Gynecologic 1Endocrine 1

Conditions

Glioblastoma 2Uterine Cervical Neoplasms 1Neuroendocrine Tumors 1Lymphoma, Follicular 1Astrocytoma 1

Interventions

Specimen Handling 150pembrolizumab 132Magnetic Resonance Spectroscopy 120Cyclophosphamide 118Biopsy 106fludarabine 90Nivolumab 61Carboplatin 55Radiotherapy 49Cisplatin 49Gemcitabine 48venetoclax 43Paclitaxel 43Cetuximab 40fludarabine phosphate 39Ipilimumab 36Fluorouracil 35atezolizumab 34Bevacizumab 33durvalumab 30Radiation 30Oxaliplatin 29X-Rays 28Leucovorin 28Dexamethasone 28Azacitidine 27Irinotecan 26Cytarabine 26Radiosurgery 24Injections 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × 90 days × Clear all
NCT04234568 2026-06-01

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
31 enrolled 16 charts
EndocrineNET

Neuroendocrine Tumors

NCT02595879 2026-05-29

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
21 enrolled 22 charts
Gynecologic

Uterine Cervical Neoplasms

NCT06860594 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Lymphoma, Follicular

NCT06410248 2026-05-01

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Northwestern University

Phase 1 Recruiting
30 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡